PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 18 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Multiple alkaloids (including melosuavines, melodinines, and 19-hydroxy-melodinine K) demonstrated cytotoxicity against breast, gastric, colon, Hela, and glioblastoma cell lines in vitro [PMID: 32272162, 27426217, 28452946, 22260257, 24274642].
Suadimin A showed significant in vitro antimycobacterial activity with an MIC90 of 6.76 μM against the H37Rv strain [PMID: 31411483].
Crude methanolic extracts and specific compounds exhibited potent antifungal activity against Colletotrichum musae, C. graminicola, C. gloeosporioides, and Alternaria musae [PMID: 28714347].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 25522534 (2014) — Two new alkaloids from Melodinus suaveolens. · Natural product communications
- 2.PMID: 25908630 (2015) — Antibacterial constituents from Melodinus suaveolens. · Chinese journal of natural medicines
- 3.PMID: 32272162 (2020) — Cytotoxic aspidosperma-type alkaloids from Melodinus suaveolens. · Fitoterapia
- 4.PMID: 27426217 (2016) — Two new compounds from Melodinus suaveolens. · Natural product research
- 5.PMID: 40412711 (2025) — Aspidosperma-type bisindole alkaloids from Melodinus suaveolens and their antiproliferative activities. · Phytochemistry